Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics

Arcus Biosciences, Inc. (RCUS): $23.13

0.04 (+0.17%)

POWR Rating

Component Grades













Add RCUS to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where RCUS ranks best; there it ranks ahead of 97.21% of US stocks.
  • The strongest trend for RCUS is in Quality, which has been heading up over the past 177 days.
  • RCUS's current lowest rank is in the Stability metric (where it is better than 1.84% of US stocks).

RCUS Stock Summary

  • With a year-over-year growth in debt of 143.54%, ARCUS BIOSCIENCES INC's debt growth rate surpasses 90.96% of about US stocks.
  • Over the past twelve months, RCUS has reported earnings growth of -129.69%, putting it ahead of only 11.73% of US stocks in our set.
  • As for revenue growth, note that RCUS's revenue has grown 1,042.97% over the past 12 months; that beats the revenue growth of 99.01% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ARCUS BIOSCIENCES INC, a group of peers worth examining would be VIR, IMTX, AEVA, SRRK, and CRNX.
  • Visit RCUS's SEC page to see the company's official filings. To visit the company's web site, go to

RCUS Valuation Summary

  • In comparison to the median Healthcare stock, RCUS's EV/EBIT ratio is 75.76% higher, now standing at 17.4.
  • RCUS's price/earnings ratio has moved up 32.6 over the prior 59 months.

Below are key valuation metrics over time for RCUS.

Stock Date P/S P/B P/E EV/EBIT
RCUS 2023-01-20 3.6 2.2 19.3 17.4
RCUS 2023-01-19 3.5 2.2 18.9 17.1
RCUS 2023-01-18 3.3 2.0 17.7 15.8
RCUS 2023-01-17 3.4 2.1 18.4 16.6
RCUS 2023-01-13 3.4 2.1 18.5 16.6
RCUS 2023-01-12 3.1 1.9 16.9 15.1

RCUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RCUS has a Quality Grade of C, ranking ahead of 31.17% of graded US stocks.
  • RCUS's asset turnover comes in at 0.109 -- ranking 257th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RCUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.109 1 -0.432
2021-03-31 0.114 1 -0.447
2020-12-31 0.138 1 -0.423
2020-09-30 0.186 1 -0.442
2020-06-30 0.056 1 -0.927
2020-03-31 0.072 1 -0.819

RCUS Stock Price Chart Interactive Chart >

Price chart for RCUS

RCUS Price/Volume Stats

Current price $23.13 52-week high $39.75
Prev. close $23.09 52-week low $16.74
Day low $22.66 Volume 965,900
Day high $23.63 Avg. volume 1,313,206
50-day MA $25.37 Dividend yield N/A
200-day MA $25.36 Market Cap 1.67B

Arcus Biosciences, Inc. (RCUS) Company Bio

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.

RCUS Latest News Stream

Event/Time News Detail
Loading, please wait...

RCUS Latest Social Stream

Loading social stream, please wait...

View Full RCUS Social Stream

Latest RCUS News From Around the Web

Below are the latest news stories about ARCUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RCUS as an investment opportunity.

Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why

Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.

Yahoo | January 25, 2023

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., January 24, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 44,300 shares of the Company’s common stock at an exercise price per share of $22.02, which was the closing price on January 23, 2023, and restricted stock units to acquire a total of 22,150

Yahoo | January 24, 2023

Amarin Corporation (AMRN) Down 13% in One Week: Here's Why

Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.

Yahoo | January 23, 2023

Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication

The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.

Yahoo | January 20, 2023

Angion (ANGN) Down on Merger Agreement With Private Biotech

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Yahoo | January 18, 2023

Read More 'RCUS' Stories Here

RCUS Price Returns

1-mo 11.85%
3-mo -7.22%
6-mo -12.22%
1-year -22.25%
3-year 163.44%
5-year N/A
YTD 11.85%
2022 -48.90%
2021 55.89%
2020 157.03%
2019 -6.22%
2018 N/A

Continue Researching RCUS

Want to see what other sources are saying about Arcus Biosciences Inc's financials and stock price? Try the links below:

Arcus Biosciences Inc (RCUS) Stock Price | Nasdaq
Arcus Biosciences Inc (RCUS) Stock Quote, History and News - Yahoo Finance
Arcus Biosciences Inc (RCUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8145 seconds.